中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
5期
807-808
,共2页
孟鲁司特%儿童支气管哮喘%复发
孟魯司特%兒童支氣管哮喘%複髮
맹로사특%인동지기관효천%복발
Montelukast%Children with bronchial asthma%Recurrence
目的：：观察孟鲁司特辅助治疗儿童支气管哮喘的疗效和不良反应及其对患儿复发的影响。方法：180例儿童支气管哮喘患儿随机分为对照组与观察组各90例。对照组采用吸氧、布地奈德联合特布他林雾化吸入、甲泼尼龙琥珀酸钠静滴等常规治疗；观察组在对照组基础上加用孟鲁司特钠片5 mg,po,qd。两组均连续治疗3个月后评价疗效,观察两组呼吸困难及喘息、哮鸣音消失时间,以及治疗期间的药品不良反应。随访3~6个月,比较两组复发情况。结果：观察组呼吸困难、喘息及哮鸣音消失时间均明显短于对照组(P<0.05)；总有效率为96.67%,明显高于对照组的73.33%(P<0.05)。两组平均随访(5.1±0.3)个月,观察组治愈后复发率为8.51%,明显低于对照组的31.43%(P<0.05)。两组治疗期间未见明显药品不良反应发生。结论：常规药物治疗基础上加用孟鲁司特迅速改善临床症状,提高治疗效果,减少治愈后复发情况,安全性高,值得临床推广应用。
目的：：觀察孟魯司特輔助治療兒童支氣管哮喘的療效和不良反應及其對患兒複髮的影響。方法：180例兒童支氣管哮喘患兒隨機分為對照組與觀察組各90例。對照組採用吸氧、佈地奈德聯閤特佈他林霧化吸入、甲潑尼龍琥珀痠鈉靜滴等常規治療；觀察組在對照組基礎上加用孟魯司特鈉片5 mg,po,qd。兩組均連續治療3箇月後評價療效,觀察兩組呼吸睏難及喘息、哮鳴音消失時間,以及治療期間的藥品不良反應。隨訪3~6箇月,比較兩組複髮情況。結果：觀察組呼吸睏難、喘息及哮鳴音消失時間均明顯短于對照組(P<0.05)；總有效率為96.67%,明顯高于對照組的73.33%(P<0.05)。兩組平均隨訪(5.1±0.3)箇月,觀察組治愈後複髮率為8.51%,明顯低于對照組的31.43%(P<0.05)。兩組治療期間未見明顯藥品不良反應髮生。結論：常規藥物治療基礎上加用孟魯司特迅速改善臨床癥狀,提高治療效果,減少治愈後複髮情況,安全性高,值得臨床推廣應用。
목적：：관찰맹로사특보조치료인동지기관효천적료효화불량반응급기대환인복발적영향。방법：180례인동지기관효천환인수궤분위대조조여관찰조각90례。대조조채용흡양、포지내덕연합특포타림무화흡입、갑발니룡호박산납정적등상규치료；관찰조재대조조기출상가용맹로사특납편5 mg,po,qd。량조균련속치료3개월후평개료효,관찰량조호흡곤난급천식、효명음소실시간,이급치료기간적약품불량반응。수방3~6개월,비교량조복발정황。결과：관찰조호흡곤난、천식급효명음소실시간균명현단우대조조(P<0.05)；총유효솔위96.67%,명현고우대조조적73.33%(P<0.05)。량조평균수방(5.1±0.3)개월,관찰조치유후복발솔위8.51%,명현저우대조조적31.43%(P<0.05)。량조치료기간미견명현약품불량반응발생。결론：상규약물치료기출상가용맹로사특신속개선림상증상,제고치료효과,감소치유후복발정황,안전성고,치득림상추엄응용。
Objective:To observe adjuvant curative effect and adverse reactions of montelukast in the treatment of children with bronchial asthma and its effect on recurrence. Methods:Totally 180 cases of children with bronchial asthma were randomly divided in-to the control group and the observation group with 90 ones in each. The control group was treated with oxygen and budesonide terbutal-ine inhalation, intravenous methylprednisolone sodium succinate and the other conventional treatment methods, and the observation group was additionally treated with montelukast sodium tablets 5 mg, po, qd. The treatment course was three months, and then expira-tory dyspnea, disappearance time of asthma and wheeze and adverse drug reactions in the two groups were evaluated. After 3-6-month follow-up, the recurrence was compared between the two groups as well. Results: The disappearance time of dyspnea, asthma and wheeze in the observation group was shorter than that in the control group (P<0. 05), the total effective rate in the observation group was 96. 67%, which was significantly higher than that in the control group (73. 33%, P<0. 05). The mean follow-up duration was (5. 1 ± 0. 3) months, and the recurrence rate was 8. 51% in the observation group, which was significantly lower than that in the con-trol group (31. 43%, P<0. 05). During the treatment, no significant adverse drug reaction was appeared in the two groups. Conclu-sion:The conventional drug treatment combined with montelukast can rapidly improve the clinical symptoms and reduce recurrence with promising safety, which is worthy of clinical application.
